Geode Capital Management
NRXP icon

Geode Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Geode Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.3M Buy
446,457
+131,798
+42% +$468K ﹤0.01% 3271
2026
Q2 		$1.29M Buy
314,659
+4,547
+1% +$15K ﹤0.01% 3293
2026
Q1 		$661K Buy
310,112
+91,246
+42% +$184K ﹤0.01% 3485
2025
Q4 		$593K Buy
218,866
+33,004
+18% +$88.6K ﹤0.01% 3533
2025
Q3 		$613K Buy
185,862
+13,607
+8% +$39K ﹤0.01% 3538
2025
Q2 		$562K Buy
172,255
+37,598
+28% +$94.2K ﹤0.01% 3518
2025
Q1 		$276K Buy
134,657
+60,406
+81% +$170K ﹤0.01% 3747
2024
Q4 		$163K Sell
74,251
-3,090
-4% -$4.15K ﹤0.01% 3961
2024
Q3 		$131K Buy
77,341
+11,682
+18% +$23.5K ﹤0.01% 4033
2024
Q2 		$160K Buy
65,659
+23,664
+56% +$84.2K ﹤0.01% 3991
2024
Q1 		$198K Buy
41,995
+803
+2% +$3.7K ﹤0.01% 3944
2023
Q4 		$190K Hold
41,192
– – ﹤0.01% 3962
2023
Q3 		$107K Buy
41,192
+3,325
+9% +$11.1K ﹤0.01% 4225
2023
Q2 		$183K Hold
37,867
– – ﹤0.01% 4080
2023
Q1 		$250K Hold
37,867
– – ﹤0.01% 3937
2022
Q4 		$420K Buy
37,867
+5,804
+18% +$58.5K ﹤0.01% 3741
2022
Q3 		$237K Buy
32,063
+1,220
+4% +$8.22K ﹤0.01% 4107
2022
Q2 		$185K Buy
30,843
+1,456
+5% +$19.1K ﹤0.01% 4316
2022
Q1 		$719K Buy
29,387
+8,237
+39% +$268K ﹤0.01% 3764
2021
Q4 		$1.01M Buy
21,150
+16,573
+362% +$1.2M ﹤0.01% 3717
2021
Q3 		$424K Buy
4,577
+1,129
+33% +$147K ﹤0.01% 4107
2021
Q2 		$400K Buy
+3,448
New +$910K ﹤0.01% 4040

Other funds holding NRXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Bleakley Financial Group
Bleakley Financial Group Fairfield, New Jersey $8.8B AUM 22.37% 1-Year Est. Return

Geode Capital Management's NRXP Position: Q3 2026 in Review

Geode Capital Management increased its NRX Pharmaceuticals (NRXP) stake by 42% in Q3 2026, buying an estimated $468K and bringing the position to 446,457 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Geode Capital Management first reported a position in NRXP in Q2 2021 and has held it in 22 quarters since. 33 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • Geode Capital Management held 446,457 shares of NRX Pharmaceuticals worth $1.3M as of Q3 2026.
  • Geode Capital Management bought 131,798 NRX Pharmaceuticals shares in Q3 2026, an estimated $468K.
  • NRX Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3271 holding.
  • Geode Capital Management first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 22 quarters since.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.